AbbVie Presents New Data at the European E|Congress of ...

AbbVie Presents New Data at the European E-Congress of ...

In addition to sharing new data from the robust Phase 3 SELECT rheumatoid arthritis clinical trial program, AbbVie will present investigational ...

AbbVie Presents New Data on Efficacy of Upadacitinib in Moderate ...

Poster presented at the 33rd European Academy of Dermatology and Venereology (EADV) Congress, September 25-28; Amsterdam, Netherlands.

AbbVie Unveils New Data from Robust Gastroenterology Portfolio at ...

... Congress of European Crohn's and Colitis Organisation (ECCO). Open a ... "Our collection of data at this year's congress is indicative ...

AbbVie Presents New Data Analyses for Growing Dermatology ...

... European Academy of Dermatology and Venereology (EADV) Congress. Open ... AbbVie Data at the 30th EADV Congress. RINVOQ (upadacitinib) ...

New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib ...

New data showcasing depth and strength across AbbVie's dermatology portfolio will be presented at the 33rd European Academy of Dermatology ...

AbbVie Presents Long-Term Data Further Supporting the Efficacy ...

... European Congress of Rheumatology, EULAR 2023, taking place from 31 May – 3 June in Milan. "These new results from the SELECT trial programs ...

AbbVie Showcases New Analyses and Real-World Data Across ...

AbbVie (NYSE: ABBV) today announced it will present 23 abstracts at the 31 st European Academy of Dermatology and Venereology (EADV) Congress.

AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO ...

AbbVie (NYSE: ABBV) today announced that new data from its innovative antibody-drug conjugate (ADC) platform will be showcased at the upcoming European Society ...

AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI ...

- Results were presented at the 30th European Academy of Dermatology and Venereology (EADV) Virtual Congress ... The new long-term data ...

AbbVie Presents New Data at the European E-Congress of ...

AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio. Start ...

AbbVie Showcases its Leadership in Rheumatology Research with ...

... New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress ... European Alliance of Associations for Rheumatology ...

AbbVie Showcases the Depth of its Rheumatology Portfolio with ...

Additionally, AbbVie will present new integrated safety data for RINVOQ from the Phase 3 SELECT clinical trials in patients with RA up to 4.5 ...

AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient ...

... Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress. - Across all doses, a ...

AbbVie Announces European Commission Approval of SKYRIZI ...

This approval introduces a new treatment option to help patients ... data collection technologies" section of our Privacy Notice. We ...

AbbVie Unveils New Data from Robust Gastroenterology Portfolio at ...

AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO). PR ...

AbbVie to Present Several Real-World Data Studies at European ...

August 30, 2022. This year's European Academy of Dermatology and Venereology (EADV) 2022 Congress will see 23 abstracts based on real-world data from ...

AbbVie Presents New Data Analyses for Growing Dermatology ...

AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology Congress.

New Data from AbbVie Will Be Presented at EADV 2022 Congress

AbbVie Inc. will present 23 abstracts at the 31st European Academy of Dermatology and Venerology (EADV) Congress in Milan, virtually and ...

November 14, 2024 - AbbVie News Center

AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology (EADV) Congress. - New ...

AbbVie to Present New Data at 27th EADV Congress

AbbVie will present new data across investigational medicines and Humira® (adalimumab) at the 27th European Academy of Dermatology and …